Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Clin Cancer Res. 2013 May 15;19(10):2646–2656. doi: 10.1158/1078-0432.CCR-12-2939

Table 1.

Phase 2 Trial Designs for SCLC

Type I,
type II
error		 Events Sample Size (Analysis time)
No follow-up 3 months follow-up 6 months follow-up 9 months follow-up
15%,15% 78 198 (10 mths) 150 (11 mths) 124 (13 mths) 108 (15 mths)
15%,10% 97 218 (12 mths) 180 (12 mths) 150 (14 mths) 132 (16 mths)
15%, 5% 130 266 (14 mths) 218 (15 mths) 192 (16 mths) 172 (18 mths)
10%,10% 120 256 (13 mths) 206 (14 mths) 178 (15 mths) 160 (17 mths)
10%, 5% 155 294 (16 mths) 252 (16 mths) 220 (18 mths) 200 (20 mths)
5%, 5% 197 350 (18 mths) 298 (19 mths) 268 (20 mths) 248 (22 mths)